The global cancer biomarker market is experiencing a period of remarkable expansion, driven by advancements in precision medicine and the increasing importance of biomarkers in cancer diagnosis, prognosis, and treatment selection. According to recent estimations, the market, valued at USD 11.1 billion in 2022, is anticipated to nearly triple in size, reaching USD 27.4 billion by 2030....